Knoll/UCSF agreement allows publication of Synthroid study; Knoll will present contrary conclusions.
KNOLL/UCSF AGREEMENT WILL ALLOW PUBLICATION OF DONG SYNTHROID ARTICLE and will provide for a forum where Knoll can present its view of University of California-San Francisco researcher Betty Dong's study of Knoll's Synthroid and competing levothyroxine products. Dong conducted her study at Knoll's request; the manuscript was withdrawn from the Journal of the American Medical Association "under pressure from Knoll," FDA charged in a Nov. 7 letter ("The Pink Sheet" Nov. 18, p. 3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth